Join
BiomX Inc. logo

PHGE

AMEX

BiomX Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2019
$0.67-0.05 (-7.33%)
News25/Ratings3

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Price$0.67-5.66 (-89.47%)
2026-03-052026-06-08
News · 26 weeks57+100%
2025-12-14: 02025-12-21: 02025-12-28: 22026-01-04: 12026-01-11: 22026-01-18: 12026-01-25: 22026-02-01: 12026-02-08: 72026-02-15: 32026-02-22: 12026-03-01: 32026-03-08: 32026-03-15: 32026-03-22: 42026-03-29: 32026-04-05: 42026-04-12: 52026-04-19: 02026-04-26: 12026-05-03: 22026-05-10: 12026-05-17: 12026-05-24: 32026-05-31: 32026-06-07: 1
2025-12-142026-06-07
Mix3390d
  • SEC Filings16(48%)
  • Other11(33%)
  • Leadership3(9%)
  • Insider2(6%)
  • M&A1(3%)

Latest news

25 items

PHGE FAQ

7 questions
  • What does BiomX Inc. do?
    BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under...
  • Where does PHGE stock trade?
    BiomX Inc. (PHGE) is listed on AMEX.
  • What sector and industry is PHGE in?
    BiomX Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did BiomX Inc. go public?
    BiomX Inc. (PHGE) completed its IPO in 2019.
  • What are analysts saying about PHGE?
    BiomX Inc. has had 3 recent analyst actions on file. The most recent action was from Chardan Capital: Buy with a $1300.00 price target on 2021-11-16. Recent price targets range from $1000.00 to $1600.00.
  • What companies are similar to PHGE?
    Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PHGE side-by-side with any of them on Quantisnow.
  • How can I track PHGE on Quantisnow?
    Quantisnow aggregates BiomX Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHGE to receive live email and push alerts on every new disclosure.